Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

Completed · Phase 3

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

The primary objective of this study is to evaluate long-term safety and patient acceptability of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol Chlorofluorocarbon-Metered Dose Inhaler (CFC-MDI) and the free combination of ATROVENT Hydrofluoroalkane (HFA) and albuterol Hydrofluoroalkane (HFA) inhalation aerosols.

Key facts

Study ID: NCT01019694
Run by: Boehringer Ingelheim
People needed: 470
Starts: 2009-11-01
Last updated by the study team: 2014-10-23

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

All patients must sign an informed consent consistent with International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines prior to participation in the trial.
Male or female patients 40 years of age or older.
Patients must be current or ex-smokers with a smoking history of 10 pack-years. (Patients who have never smoked cigarettes must be excluded) Pack Years = Number of cigarettes/day x years of smoking 20 cigarettes/pack
All patients must have a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) (P95-4381), and must meet the following spirometric criteria at Visit 1:Relatively stable, moderate to severe airway obstruction with a post-bronchodilator Forced Expiratory Volume in one second (FEV1) < 80% of predicted normal and FEV1/Forced Vital Capacity (FVC) < 70%. Spirometry should be done at baseline and approximately 1/2 hour following 4 inhalations of albuterol. Predicted normal values will be calculated according to European Coal and Steel Community (ECSC), European Community for Coal and Steel (ECCS), (R94-1408). For Height measured in inches Males: FEV1 predicted (L) = 4.30 x [height (inches) / 39.37]-0.029 x age (yrs) - 2.49 Females: FEV1 predicted (L) = 3.95 x [height (inches) / 39.37]-0.025 x age (yrs) - 2.60 For Height measured in meters Males: FEV1 predicted (L) = 4.30 x [height (meters)] - 0.029 x age (years) -2.49 Females: FEV1 predicted (L) = 3.95 x [height (meters)] - 0.025 x age (years) - 2.60
Patients must be able to perform all study related procedures and maintain study records during the study period as required in the protocol.
Patients must be able to inhale medication in a competent manner from the RESPIMAT inhaler and from a metered dose inhaler (MDI).

You may not qualify if…

Patients with significant diseases other than COPD will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study.
Patients with a recent history (i.e., one year or less) of myocardial infarction.
Patients who have been hospitalized or being treated for heart failure within the past year.
Patients with clinically unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy within the past year.
Patients with a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with fully cured squamous cell or treated basal cell carcinoma are allowed).
Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis.
Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of a thoracotomy for other reasons should be evaluated as per exclusion criterion No. 1.
Patients with a current diagnosis of asthma.
Patients with a history of significant alcohol or drug abuse.
Patients with known active tuberculosis.
Patients using beta blocker medications are excluded. Cardioselective beta blockers are allowed with caution. Beta blocker eye medications for treatment of non-narrow angle glaucoma are allowed.
Patients who regularly use daytime oxygen therapy for more than 1 hour per day Continuous Positive Airway Pressure (CPAP for sleep apnea is allowed).
Patients using oral corticosteroid medication at a dose in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day, except as required for treatment of exacerbation during the study.
Pregnant or nursing women.
Women of childbearing potential not using a medically approved means of contraception (i.e., oral or injectable contraceptives, intrauterine devices or diaphragm with spermicide, or transdermal hormonal patches). Abstinence will not be accepted as a medically approved means of contraception. Female patients will be considered to be of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation, or post-menopausal for at least two years.
Patients with known hypersensitivity to anticholinergic drugs, any other component of the ipratropium bromide/albuterol RESPIMAT solution including Benzalkonium chloride (BAC) and Ethylenediaminetetraacetic acid (EDTA) or the ipratropium bromide/albuterol Chlorofluorocarbons (CFC) MDI or Hydrofluoroalkane (HFA) components.
Previous participation in this study. (The patient cannot re-enroll into this study.)
Patients who are currently participating in another interventional study.
Patients who have taken an investigational drug within 1 month or 6 half lives (whichever is greater) prior to screening.
Patients currently in any pulmonary rehabilitation program or scheduled to participate in any such program during the study period.

Where it is running

1012.62.145 Boehringer Ingelheim Investigational Site — Mobile, Alabama, United States
1012.62.156 Boehringer Ingelheim Investigational Site — Mesa, Arizona, United States
1012.62.135 Boehringer Ingelheim Investigational Site — Berkeley, California, United States
1012.62.141 Boehringer Ingelheim Investigational Site — Riverside, California, United States
1012.62.155 Boehringer Ingelheim Investigational Site — Boulder, Colorado, United States
1012.62.126 Boehringer Ingelheim Investigational Site — Fort Collins, Colorado, United States
1012.62.131 Boehringer Ingelheim Investigational Site — Wheat Ridge, Colorado, United States
1012.62.144 Boehringer Ingelheim Investigational Site — Stamford, Connecticut, United States
1012.62.123 Boehringer Ingelheim Investigational Site — Waterbury, Connecticut, United States
1012.62.114 Boehringer Ingelheim Investigational Site — Clearwater, Florida, United States
1012.62.124 Boehringer Ingelheim Investigational Site — DeLand, Florida, United States
1012.62.139 Boehringer Ingelheim Investigational Site — Pensacola, Florida, United States
1012.62.134 Boehringer Ingelheim Investigational Site — Tampa, Florida, United States
1012.62.115 Boehringer Ingelheim Investigational Site — Winter Park, Florida, United States
1012.62.146 Boehringer Ingelheim Investigational Site — Decatur, Georgia, United States
1012.62.113 Boehringer Ingelheim Investigational Site — Coeur d'Alene, Idaho, United States
1012.62.157 Boehringer Ingelheim Investigational Site — Dubuque, Iowa, United States
1012.62.159 Boehringer Ingelheim Investigational Site — Louisville, Kentucky, United States
1012.62.116 Boehringer Ingelheim Investigational Site — Lafayette, Louisiana, United States
1012.62.148 Boehringer Ingelheim Investigational Site — New Orleans, Louisiana, United States
1012.62.137 Boehringer Ingelheim Investigational Site — North Dartmouth, Massachusetts, United States
1012.62.132 Boehringer Ingelheim Investigational Site — Ann Arbor, Michigan, United States
1012.62.117 Boehringer Ingelheim Investigational Site — Livonia, Michigan, United States
1012.62.158 Boehringer Ingelheim Investigational Site — Minneapolis, Minnesota, United States
1012.62.153 Boehringer Ingelheim Investigational Site — Jasper, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.